Florence Sens, Maurice Laville, Laure Groisne, David Ciabrini
{"title":"[肾保护的新进展]。","authors":"Florence Sens, Maurice Laville, Laure Groisne, David Ciabrini","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>NEWS IN NEPHROPROTECTION. Nephroprotection aims to preserve kidney function and slow the progression of chronic kidney disease. Recent decades have been marked by an expansion of therapeutic options, likely to reduce the number of patients reaching the stage of end-stage renal failure. Among these advances, inhibitors of sodium-glucose cotransport type II (iSGLT2), glucagon like peptide-1 analogues and non-steroidal mineralocorticoid receptor antagonists occupy a central place, in addition to conventional strategies, such as hygienic-dietary measures and blockers of the renin-angiotensin-aldosterone system. This article provides an overview of recent advances in the field of cardio-nephroprotection of adult patients with chronic kidney disease, with particular emphasis on the role and conditions of use of iSGLT2, also called gliflozins.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"239-246"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[New s in nephroprotection].\",\"authors\":\"Florence Sens, Maurice Laville, Laure Groisne, David Ciabrini\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>NEWS IN NEPHROPROTECTION. Nephroprotection aims to preserve kidney function and slow the progression of chronic kidney disease. Recent decades have been marked by an expansion of therapeutic options, likely to reduce the number of patients reaching the stage of end-stage renal failure. Among these advances, inhibitors of sodium-glucose cotransport type II (iSGLT2), glucagon like peptide-1 analogues and non-steroidal mineralocorticoid receptor antagonists occupy a central place, in addition to conventional strategies, such as hygienic-dietary measures and blockers of the renin-angiotensin-aldosterone system. This article provides an overview of recent advances in the field of cardio-nephroprotection of adult patients with chronic kidney disease, with particular emphasis on the role and conditions of use of iSGLT2, also called gliflozins.</p>\",\"PeriodicalId\":94123,\"journal\":{\"name\":\"La Revue du praticien\",\"volume\":\"75 3\",\"pages\":\"239-246\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"La Revue du praticien\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue du praticien","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
NEWS IN NEPHROPROTECTION. Nephroprotection aims to preserve kidney function and slow the progression of chronic kidney disease. Recent decades have been marked by an expansion of therapeutic options, likely to reduce the number of patients reaching the stage of end-stage renal failure. Among these advances, inhibitors of sodium-glucose cotransport type II (iSGLT2), glucagon like peptide-1 analogues and non-steroidal mineralocorticoid receptor antagonists occupy a central place, in addition to conventional strategies, such as hygienic-dietary measures and blockers of the renin-angiotensin-aldosterone system. This article provides an overview of recent advances in the field of cardio-nephroprotection of adult patients with chronic kidney disease, with particular emphasis on the role and conditions of use of iSGLT2, also called gliflozins.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
